Akèy › Myelofibroz › Washington › Seattle
Etid klinik pou Myelofibroz nan Seattle, WA
11 etid pou Myelofibroz ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Ap rekriteFaz 1/2
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Ap rekriteFaz 3
- Fred Hutch Cancer Research, Seattle
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Ap rekriteFaz 3
- University of Washington, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Ap rekriteFaz 1/2
- University of Washington, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Ap rekriteFaz 2
- GSK Investigational Site, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Seattle
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Ap rekriteFaz 3
- Fred Hutchinson Cancer Centre, Seattle
Etid Myelofibroz nan lòt vil
- Houston, TX19 etid
- New York City, NY18 etid
- Boston, MA12 etid
- Durham, NC12 etid
- Columbus, OH11 etid
- Salt Lake City, UT10 etid
- Miami, FL10 etid
- Nashville, TN9 etid
- Cleveland, OH9 etid
- Tampa, FL9 etid
- Atlanta, GA9 etid
- Baldwin Park, CA9 etid
Lòt etid nan Seattle
- Kansè Poumon ki pa ti selil53 etid
- Kansè (tout kalite)49 etid
- Kansè pwostat42 etid
- Leksemi mieloïd egi40 etid
- Kansè nan tete39 etid
- Kansè Metastatik39 etid
- Kansè kolorektal34 etid
- Kansè poumon33 etid
- Kansè ovè30 etid
- Myelom Miltip22 etid
- Sendwòm myelodisplastik21 etid
- Leksemi limfoblastik egi21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.